Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Long-Term Deferred Tax (2018)

Denali Therapeutics (DNLI) has disclosed Long-Term Deferred Tax for 3 consecutive years, with $12.0 million as the latest value for Q4 2023.

  • On a quarterly basis, Long-Term Deferred Tax changed N/A to $12.0 million in Q4 2023 year-over-year; TTM through Dec 2023 was $12.0 million, a N/A change, with the full-year FY2023 number at $12.0 million, changed N/A from a year prior.
  • Long-Term Deferred Tax was $12.0 million for Q4 2023 at Denali Therapeutics, down from $150.5 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $150.5 million in Q4 2020 to a low of $12.0 million in Q4 2023.